469 related articles for article (PubMed ID: 19602530)
21. Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.
Wielage RC; Bansal M; Andrews JS; Klein RW; Happich M
Appl Health Econ Health Policy; 2013 Jun; 11(3):219-36. PubMed ID: 23616247
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities.
Katz JN; Smith SR; Collins JE; Solomon DH; Jordan JM; Hunter DJ; Suter LG; Yelin E; Paltiel AD; Losina E
Osteoarthritis Cartilage; 2016 Mar; 24(3):409-18. PubMed ID: 26525846
[TBL] [Abstract][Full Text] [Related]
23. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
Scheiman JM; Hindley CE
Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
[TBL] [Abstract][Full Text] [Related]
24. Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis.
Jansen JP; Gaugris S; Choy EH; Ostor A; Nash JT; Stam W
Pharmacoeconomics; 2010; 28(4):323-44. PubMed ID: 20222755
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Cannon CP; Curtis SP; FitzGerald GA; Krum H; Kaur A; Bolognese JA; Reicin AS; Bombardier C; Weinblatt ME; van der Heijde D; Erdmann E; Laine L;
Lancet; 2006 Nov; 368(9549):1771-81. PubMed ID: 17113426
[TBL] [Abstract][Full Text] [Related]
26. An economic model of long-term use of celecoxib in patients with osteoarthritis.
Loyd M; Rublee D; Jacobs P
BMC Gastroenterol; 2007 Jul; 7():25. PubMed ID: 17610716
[TBL] [Abstract][Full Text] [Related]
27. Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity.
Yuan JQ; Tsoi KK; Yang M; Wang JY; Threapleton DE; Yang ZY; Zou B; Mao C; Tang JL; Chan FK
Aliment Pharmacol Ther; 2016 Jun; 43(12):1262-75. PubMed ID: 27121479
[TBL] [Abstract][Full Text] [Related]
28. Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis.
van Walsem A; Pandhi S; Nixon RM; Guyot P; Karabis A; Moore RA
Arthritis Res Ther; 2015 Mar; 17(1):66. PubMed ID: 25879879
[TBL] [Abstract][Full Text] [Related]
29. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland.
Chancellor JV; Hunsche E; de Cruz E; Sarasin FP
Pharmacoeconomics; 2001; 19 Suppl 1():59-75. PubMed ID: 11280106
[TBL] [Abstract][Full Text] [Related]
30. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective.
Marshall JK; Pellissier JM; Attard CL; Kong SX; Marentette MA
Pharmacoeconomics; 2001; 19(10):1039-49. PubMed ID: 11735672
[TBL] [Abstract][Full Text] [Related]
31. Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis.
El-Serag HB; Graham DY; Richardson P; Inadomi JM
Arch Intern Med; 2002 Oct; 162(18):2105-10. PubMed ID: 12374519
[TBL] [Abstract][Full Text] [Related]
32. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
Chan FK; Lanas A; Scheiman J; Berger MF; Nguyen H; Goldstein JL
Lancet; 2010 Jul; 376(9736):173-9. PubMed ID: 20638563
[TBL] [Abstract][Full Text] [Related]
33. The Cost-effectiveness of Celecoxib versus Non-steroidal Anti-inflammatory Drugs plus Proton-pump Inhibitors for Treating Osteoarthritis in Algeria.
Hammoumraoui N; Kherraf SA; Mould-Quevedo J; Ismail TA
J Health Econ Outcomes Res; 2013; 1(2):184-199. PubMed ID: 37662022
[No Abstract] [Full Text] [Related]
34. The use of NSAIDs in rheumatic disorders 2005: a global perspective.
Kean WF; Buchanan WW
Inflammopharmacology; 2005; 13(4):343-70. PubMed ID: 16354389
[TBL] [Abstract][Full Text] [Related]
35. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
[TBL] [Abstract][Full Text] [Related]
36. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk.
Moore RA; Derry S; McQuay HJ
BMC Musculoskelet Disord; 2007 Aug; 8():73. PubMed ID: 17683540
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective.
Wielage R; Bansal M; Wilson K; Klein R; Happich M
Spine (Phila Pa 1976); 2013 May; 38(11):936-46. PubMed ID: 23250234
[TBL] [Abstract][Full Text] [Related]
38. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
Spiegel BM; Targownik L; Dulai GS; Gralnek IM
Ann Intern Med; 2003 May; 138(10):795-806. PubMed ID: 12755551
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis.
Yun HR; Bae SC
Rheumatol Int; 2005 Jan; 25(1):9-14. PubMed ID: 13680139
[TBL] [Abstract][Full Text] [Related]
40. Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis.
Jarupongprapa S; Ussavasodhi P; Katchamart W
J Gastroenterol; 2013 Jul; 48(7):830-8. PubMed ID: 23208017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
